Ethnic disparities in presentation but not outcome in multiple myeloma patients: a multicenter retrospective study in Northern Israel.

Multiple myeloma disparity ethnicity overall survival progression-free survival

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
15 Sep 2023
Historique:
medline: 16 9 2023
pubmed: 16 9 2023
entrez: 15 9 2023
Statut: aheadofprint

Résumé

Several studies showed ethnic disparities in multiple myeloma (MM) incidence and prognosis. In order to compare prognosis and overall survival between different ethnic groups, a multicenter retrospective study was conducted in Northern Israel. A total of 145 patients suffering from MM were included (72% Jewish, and 28% Arabs) who were treated between 2008-2018. A difference was found in the stage of the disease at the time of diagnosis, patients of Arab origin were diagnosed at a more advanced stage (III), (53.7% vs. 33.7%, respectively). A mortality rate of 48.9% was found in the study, regardless of population ethnic origin. No significant differences in rates of MGUS, MM symptoms, treatments, or progression-free survival (PFS) and overall survival (OS) were observed between ethnic groups. This suggests that raising awareness of MM may result in an earlier diagnosis, especially among patients of Arab origin, preventing unnecessary suffering from these patients.

Identifiants

pubmed: 37715316
doi: 10.1080/10428194.2023.2251072
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-8

Auteurs

Najib Dally (N)

Hematology Institute Ziv Medical Center, Safed, Israel.
Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.

Myriam Baranes (M)

Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.

Luiza Akria (L)

Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Hematology Institute the Galilee Medical Center, Naharia, Israel.

Marat Kashlikov (M)

Hematology Institute Ziv Medical Center, Safed, Israel.

Khalil Tarabia (K)

Hematology Institute Ziv Medical Center, Safed, Israel.

Adi Sharabi-Nov (A)

Hematology Institute Ziv Medical Center, Safed, Israel.
Tel-Hai Academic College, Kiryat Shmona, Israel.

Celia Suriu (C)

Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Hematology Institute the Galilee Medical Center, Naharia, Israel.

Andrei Braester (A)

Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
Hematology Institute the Galilee Medical Center, Naharia, Israel.

Classifications MeSH